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Two potent anti-MRSA tanshinone glycosides (1 and 2) were discovered by targeted microbial
biotransformation, along with rapid identiﬁcation via MS/MS networking. Serial reactions including
dehydrogenation, demethylations, reduction, glycosylation and methylation have been observed after
incubation of tanshinone IIA and fungus Mucor rouxianus AS 3.3447. In addition, tanshinosides B (2)
showed potent activities against serial clinical isolates of oxacillin-resistant Staphylococcus aureus with
MIC values of 0.78 mg/mL. This is the ﬁrst study that shows a signiﬁcant increase in the level and activities
of tanshinone glycosides relative to the substrate tanshinone IIA.
© 2016 Production and hosting by Elsevier B.V. on behalf of KeAi Communications Co. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Natural products have various biological activities and are a rich
source of compounds in drug discovery [1e3]. However, drug dis-
covery from natural products has diminished in the past two de-
cades, because of decreased ﬁnancial assistance, technical barriers
to screening natural products using a high-throughput assay
against molecular targets, and lack of reliability and efﬁcient de-
replication of natural products. The renaissance of natural prod-
ucts depends on the development of new techniques for quick
identiﬁcation of novel natural products, development of efﬁcient
tools for genome mining, and the discovery of new horizons for
drug leads [4e12].ang), liuxt2010@gmail.com
nications Co., Ltd.
er B.V. on behalf of KeAi CommunLead compounds from natural sources and their structure-based
functional optimization have become increasingly valuable as tools
for investigation of the fundamental aspects of biological systems
[13]. Biotransformation is regarded as enzyme-catalyzed reaction
using enzymes, microorganisms or cell suspension cultures. It has
been shown to be a powerful addition to the expanding array of
synthetic strategies for the generation and optimization of lead
compounds in drug discovery and development [14e20]. The ad-
vantages of biotransformation are incremental regio- and stereo
selectivity and its environment friendly nature. Compared to
organic synthesis, it is an alternative method of structural modiﬁ-
cation for obtaining optically pure compounds and providing efﬁ-
cient routes to targeted products. Currently, the challenge for
biotransformation is to ﬁgure out strains which contains active
enzymes to modiﬁcation of the substrates. As depicted in the re-
view of biotransformation [18e20], the discovery of potential
strains needed hard and time-consuming screen traditionally.
Hence, it is necessary to improve the classical screening method for
a rapid and targeted screening platform [21].ications Co. This is an open access article under the CC BY-NC-ND license (http://
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bioassay-guided isolation approach, especially those are effective
against drug-resistant pathogens [22e24]. Activity screening using
the constructed Natural Product Library (NPL) was performed in
our laboratory and the results revealed that tanshinone IIA (Tan IIA,
5), the predominant substance in Chinese herb Salvia miltiorrhiza,
possessed anti-bacterial activity against Staphylococcus aureus and
has a minimum inhibitory concentration (MIC) of 3.125 mg/mL,
while it was not effective against methicillin-resistant S. aureus
(MRSA). Recently, the emergence of drug-resistant organisms, such
as MRSA and vancomycin-resistant S. aureus (VRSA), has made
treatment difﬁcult and increased the rate of mortality [25,26]. We
aimed to improve the anti-MRSA and anti-SA activities of Tan IIA by
a targeted biotransformation screen. In our work, a rapid and efﬁ-
cient microbial screening procedure was developed utilizing a 24-
well plate, according to the method developed by Stahl et al.
[27,28]. A total of 203microbial strains have been screened for their
biotransformation activities on Tan IIA, including 87 fungi
(Table S5) and 116 endophytic microbes from Traditional Chinese
Medicines (TCMs) plants (Table S6). All strains were selected from
our in-house strain library based on two criteria: a) Strains which
can modify structures of terpenoids through biotransformation
[29e31]; b) endophytic microorganisms isolated from plants,
which are more likely to recognize and process natural products of
plant origin.
Based on HPLC-DAD-UV analysis and activity evaluation, Mucor
rouxianus 3.3447 was selected as the most promising strain since it
showed the best activity among the fractions. Then, an MS/MS
network was generated on the MS2 data set from biotransformed
extract of M. rouxianus 3.3447, which revealed a number of new
products structurally related to Tan IIA. Scale-up fermentation was
performed and a series of new glycoside analogs of Tan IIA, tan-
shinosides AeD (1e4) (Fig. 1), were identiﬁed based on bioassay-
guided puriﬁcation and different NMR techniques. Thus, an MS/
MS network-assisted microtiter-targeted biotransformation plat-
form was established in this study as shown in Fig. 2.Fig. 1. Structure of isolated tanshinosides AeD (12. Material and methods
2.1. General experimental details
The optical rotation was measured using a Perkin-Elmer Model
343 polarimeter with a 5 cm cell. The UVevis spectrawere obtained
on a Cary 50 spectrophotometer. IR spectrum was recorded on a
Nicolet 5700 FT-IR Microscope spectrometer (FT-IR Microscope
Transmission). The NMR spectra were obtained on a Bruker Avance
DRX600 spectrometer. Chemical shifts were calibrated internally
against residual solvent signals (DMSO-d6: dC 39.5, dH 2.50). HRE-
SIMS measurements were obtained on Agilent 1200 HPLC/6520
QTOF-MS. ODS-A (Octadecylsilyl-A, YMC, 150 mm, AA12SA5) were
used for puriﬁcation. HPLC was performed using Agilent 1200 Se-
ries HPLC controlled using ChemStation Rev.B.02.01. Energy mini-
mization (MM2) of structures was performed using Chem3D 12.0.
(Cambridge Soft). Tanshinone IIA was purchased from Xi'an Hao-
Xuan Bio-Tech Co., Ltd.2.2. Micro-titer biotransformation screening
All strains were cultured on agar plates and stored in the fridge
at 4 C. Then, 1.0 mL sterile saline water (0.8% [m/v]) was added to
the agar dish for each strain. After washing the spores to remove
the mycelia, the conidial suspension was prepared by transferring
0.5 mL saline water into the wells of a 24-well cell culture plate
(3 mL total volume capacity), which contained 0.5 mL of 50%
glycerol. This procedure was repeated for each strain, and the 24-
well cell plates (master plates) were stored at 80 C until use.
Each conidial suspension (200 mL) from the master plates was
inoculated into a corresponding well in a 24-well plate (10 mL total
volume capacity) (assay plates) containing 2 mL of the media using
a multichannel pipette. For actinomycetes, ISP2 was chosen as the
culturemediumwhereas for fungi, potato dextrose broth (PDB) was
selected as the culture medium. After 72 h of incubation at 28 C
and 140 rpm in a shaker, 0.15 mg of Tan IIA in 20 mL methanol ande4), tanshinone IIA (5) and tanshinone I (6).
Fig. 2. Process of targeted micro-titer microbial biotransformation for anti-infective compounds. I. Rapid micro-titer microbial biotransformation screening: a) 203 microbes were
selected for this study; b) Master plates with a spore solution were stored in a 80 C freezer; c) Assay plates, containing 2 mL medium and 100 mL spores solution transferred from
master plates; d) EtOAc extraction of the fermentation broth; e) HPLC-DAD-UV analysis of EtOAc extract. The samples containing potential new products were highlighted for
further ﬂash chromatographic fractionation; f) antibacterial evaluation of the fractions. A heat map was generated to indicate the most promising samples; g) The MS/MS data were
collected and MS/MS networking was applied to identify the bioconverted products rapidly. II. Starting substrate: Tan IIA, isolated from TCM S. miltiorrhiza. III. Large-scale
fermentation and isolation of biotransformed compounds and their structures were determined by means of spectroscopic techniques.
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controls used were sterile medium to which the substrate was
added and incubated without microorganisms. The culture controls
consisted of fermentation blanks in which the organisms were
grown under identical conditions but without the substrate. All the
samples were extracted with 2 mL EtOAc by ultrasonic processing
for 10 min. The residue was prepared for the activity test and HPLC
analysis.2.3. NanoMate-LTQ-FT MS instrument parameters
Data collection was performed using a nanoMate ionization
source coupled to a Thermo LTQ-FT-ICR Mass Spectrometer. All
analyses were performed in positive ion mode in the mass range of
m/z from 100 to 2000. Both the primary and nanospray capillaries
were 150 mm o.d.  50 mm i.d. The spray voltage was maintained
between 2.0 and 3.0 kV depending on the solvent, with the solvents
being acetonitrile-water-formic acid (6:4:1).2.4. Molecular networking
The data was converted to the mzXML format, which is a text-
based format used to represent mass spectrometry data
describing the scan number, precursorm/z, andm/z and intensity of
each ion observed in the MS/MS, using ReadW from Thermo or
msconvert, part of the ProteoWizard package. Molecular networkswere generated as previously described [9,10].2.5. Cultivation, extraction, isolation, and puriﬁcation
All microorganisms screened in our experiments were obtained
from our in-house microorganism collections. Stock cultures of the
fungi were stored on PDA slants (potato 20%, dextrose 2%, and agar
2%, natural pH) at 4 C. Seed cultures were obtained by transferring
fungi from stock cultures to PDB (potato 20% and dextrose 2%,
natural pH). Flask scale biotransformation was carried out in
250 mL Erlenmeyer ﬂasks containing 50 mL of medium. The ﬂasks
were placed on a rotary shaker operating at 220 rpm at 28 C. After
3 days of incubation, the substrates (0.2 mL, 10 mg/mL, methanol
and DMSO 1:1 [v/v]) were added into each ﬂask, and these ﬂasks
were maintained under fermentation conditions for 5 days. The
cultures were then pooled and ﬁltered. The ﬁltrates were extracted
three times with equal volumes of EtOAc, and the extractions were
evaporated in vacuo and analyzed by TLC and HPLC. The culture
controls consisted of fermentation blanks in which fungi were
grown without substrate but fed with the same amount of meth-
anol and DMSO 1:1 [v/v]. Substrate controls were composed of
sterile medium to which the substrate was added and incubated
without fungi.
The preparative scale biotransformation of tanshinone IIA was
carried out in 40  1000 mL ﬂasks each containing 300 mL of PDB.
Strain AS 3.3447 was incubated for 3 days before 15 mg of
W. He et al. / Synthetic and Systems Biotechnology 1 (2016) 187e194190tanshinone IIA (2 mL, methanol and DMSO 1:1 [v/v]) was fed to
each ﬂask. The incubation conditions and extraction process were
the same as described above and afforded a crude extract (3.54 g).
The extract was subjected to column chromatography on a silica gel
(30 g). The columnwas eluted with cyclohexane-acetone (gradient,
100:1e1:1), which yielded fractions 1e6. Fraction 3 (cyclohexane-
acetone 4:1, 500 mg) was chromatographed on ODS-MPLC
(35  2.2 cm) column using the gradient elution from 10 to 80%
acetonitrile/H2O to provide 8 sub-fractions (AeH). Sub-fraction C
(50 mg) was puriﬁed using reverse-phase HPLC (Zorbax XDB-C8
250  9.4 mm, 5 mm column, 2 mL/min, isocratic elution with 45%
ACN/H2O) to yield tanshinoside A (1) (tR ¼ 25.4 min; 5.0 mg) and
tanshinoside B (2) (tR ¼ 27.6 min; 3.0 mg). Then sub-fraction D
(100 mg) was puriﬁed by reverse-phase HPLC (Zorbax SB-C3
250  9.4 mm, 5 mm column, 2 mL/min, isocratic elution with 42%
ACN/H2O) to give tanshinoside C (3) (tR ¼ 28.0 min; 2.4 mg) and
tanshinoside D (4) (tR ¼ 30.4 min; 8.0 mg).2.6. Characterization of compounds
2.6.1. Tanshinoside A (1)
Red powder: [a]24Dþ48.6 (c 0.035,MeOH); UV (MeOH) lmax (log
ε) 273 (2.06), 196 (1.33) nm; NMR data, see Table 1 and Supporting
Information Table S1.2.6.2. Tanshinoside B (2)
Red powder: [a]24D þ 30.0 (c 0.05, MeOH); UV (MeOH) lmax (log
ε) 273 (0.81), 194 (0.74) nm; NMR data, see Table 1 and Supporting
Information Table S2.2.6.3. Tanshinoside C (3)
Yellow powder: [a]24D þ 101 (c 0.05, MeOH); UV (MeOH) lmax
(log ε) 260 (0.65) nm; NMR data, see Table 1 and Supporting
Information Table S3.Table 1
1H (600 MHz) and13C NMR (150 MHz) NMR data (DMSO-d6) of 1e4.
Position 1 2
dH, mult (J in Hz) dC dH, mult (J in Hz) dC
1 9.75, d (8.6) 126.2 9.75, m 127.
2 7.55, dd (8.6, 7.0) 126.6 7.41, m 124.
3 7.48, d (7.0) 127.0 7.42, m 127.
4 e 134.0 e 133.
5 e 130.4 e 130.
6 8.08, d (9.2) 123.3 7.90, d (9.2) 121.
7 8.19, d (9.2) 118.3 8.11, d (9.2) 118.
8 e 116.6 e 112.
9 e 117.0 e 122.
10 e 130.7 e 129.
11 e 144.0 e 137.
12 e 136.0 e 148.
13 e 116.2 e 116.
14 e 144.8 e 148.
15 7.82, br.d (1.5) 142.4 7.84, s 141.
16 e 120.0 e 116.
17 2.47, s 9.49 2.43, s 9.
18 2.74, s 20.1 2.68, s 20.
19 e e e e
10 4.72, d (8.0) 106.6 4.73, d (8.2) 107.
20 3.48, m 74.1 3.62, m 74.
30 3.32, m 76.1 3.31, m 76.
40 3.22, m 69.8 3.25, m 69.
50 3.22, m 77.5 3.03, m 77.
60 3.52, 3.71, m 61.0 3.31, 3.38, m 60.
11eOH 10.03, br.s e e e
12eOCH3 e e e e2.6.4. Tanshinoside D (4)
Red powder: [a]24Dþ 115 (c 0.06, MeOH); lmax (log ε) 260 (2.05),
253 (1.59) nm NMR data, see Table 1 and Supporting Information
Table S4.
2.7. Bioassays
2.7.1. General antimicrobial assays
Antimicrobial assays were performed according to the Antimi-
crobial Susceptibility Testing Standards outlined by the Clinical and
Laboratory Standards Institute (CLSI) using the bacteria Staphylo-
coccus aureus (ATCC 6538), methicillin-resistant Staphylococcus
aureus (MRSA), oxacillin-resistant S. aureus (8e24), oxacillin-
resistant S. aureus (6281), Pseudomonas aeruginosa (PAO1), and
Bacillus subtilis (ATCC 6633). For each organism, a loopful of glycerol
stock was streaked on an LB-agar plate, which was incubated
overnight at 37 C. A single bacterial colony was selected and sus-
pended in Mueller-Hinton Broth to approximately 1  105 CFU/mL.
A two-fold serial dilution of each compound to be tested
(4000e31.3 mg/mL in DMSO) was prepared, and an aliquot of each
dilution (2 mL) was added to a 96-well ﬂat-bottom microtiter plate
(Greiner). Vancomycin and ciproﬂoxacin were used as positive
controls and DMSO as the negative control. An aliquot (78 mL) of
bacterial suspension was then added to each well (to give ﬁnal
compound concentrations of 100e0.78 mg/mL in 2.5% DMSO), and
the plate was incubated at 37 C aerobically for 16 h. Finally, the
optical density of each well at 600 nm was measured with an
EnVision 2103 Multi-label Plate Reader (Perkin-Elmer Life Sci-
ences). Theminimum inhibitory concentrations (MIC) were deﬁned
as the minimum concentration of each compound that inhibited
visible bacterial growth. All the experiments were performed in
triplicate [32].
2.7.1.1. Anti-BGC assay. The Bacillus CalmetteeGuerin (BCG) anti-
microbial assay was performed with a strain of Mycobacterium3 4
dH, mult (J in Hz) dC dH, mult (J in Hz) dC
6 2.73, m 27.5 2.98, 3.98, m 31.0
6 1.73, m 18.7 1.51, 1.85, m 20.0
3 1.64, m 37.9 1.65, m 38.8
1 e 34.0 e 34.7
9 e 147.3 e 142.7
2 7.56, d (8.2) 127.8 7.40, d (8.5) 123.4
1 7.41, d (8.2) 127.7 7.83, d (8.5) 116.3
1 e 133.2 e 132.4
1 e 132.6 e 126.2
0 e 125.3 e 114.2
1 e 167.2 e 136.2
9 e 163.7 e 142.7
4 e 114.3 e 115.3
9 e 155.7 e 148.6
7 7.50, s 140.7 7.74, s 141.1
4 e 120.8 e 116.7
53 2.09, s 9.67 2.38, s 9.50
2 1.29, s 31.5 1.30, s 31.5
1.29, s 31.5 1.28, s 32.5
4 5.41, d (7.6) 94.7 4.41, d (8.0) 107.6
3 3.02, m 72.1. 3.44, m 74.1
1 3.21, m 77.7 3.23, m 76.1
7 3.07, m 69.7 3.21, m 69.8
1 3.21, m 76.5 3.05, m 77.1
9 3.45, 3.69, m 61.0 3.44, 3.56, m 61.2
e e e e
3.65, s 51.2 e e
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rescent Protein (GFP) expression vector (pUV3583c-GFP) using
direct readout of ﬂuorescence as a measure of bacterial growth, as
described previously. The BCG strain was pre-cultivated to mid-log
phase (7 d) at 37 C in Middlebrook 7H9 broth (40 mL; Difco)
supplemented with 10% OADC enrichment (Becton Dickinson),
0.05% Tween-80, and 0.2% glycerol and then diluted to an OD600 of
0.025 with culture medium as bacterial suspension. A two-fold
serial dilution of each compound to be tested (4000e31.3 mg/mL
in DMSO), was prepared and an aliquot of each dilution (2 mL) was
added to a 96-well ﬂat-bottom microtiter plate (Greiner). Isoniazid
was used as the positive control and DMSO as the negative control.
An aliquot (78 mL) of the BCG-GFP bacterial suspension was then
added to each well (to give ﬁnal compound concentrations of
100e0.78 mg/mL in 2.5% DMSO), and the plate was incubated at
37 C for 3 d. Mycobacterial growth was determined by measuring
GFP-ﬂuorescence using an EnVision 2103 Multi-label Plate Reader
(Perkin-Elmer Life Sciences) with excitation at 485 nm and emis-
sion at 535 nm. All the experiments were performed in triplicate.
MIC was deﬁned as the minimum concentration that inhibited
more than 90% of bacteria growth [33].
2.7.2. Time-kill experiments
Time-kill analysis was performed according to CLSI method
M26-A.20. S. aureus (ATCC 6538) and methicillin-resistant S. aureus
(MRSA, clinical strain obtained from Chaoyang hospital) was
cultured overnight at 37 C in MHB broth. The single colonies were
picked and adjusted to approximately 105 CFU/mL with Mueller-
Hinton broth as bacterial suspension. Either compound, adjusted
to ﬁnal concentrations of 0.5, 2, and 8 times the MIC, or DMSO, was
then added. At 0, 2, 4, 6, 8, 10, and 24 h of incubation, 10 mL aliquots
were taken from each group, serially diluted inMHB, plated onto LB
plates, and incubated at 37 C for 24 h for a viable count enumer-
ation. The rates of killing were determined by measuring the
reduction in numbers of viable bacteria (log10 CFU/mL) at 0, 1, 2, 4,
6, 8, 10, and 24 h with ﬁxed concentrations of the compound. The
experiments were performed in duplicate. If plates contained fewer
than 10 cfu/mL, the number of colonies was considered to be below
the limit of quantitation. Culture samples containing the compound
were diluted at least 10-fold to minimize drug carryover to the LB
plates. Bactericidal activity is deﬁned as a 3-log reduction in the
initial CFU count within 24 h. The compound was considered to be
bacteriostatic at a concentration that reduced the original inoculum
by 0e3 log10 CFU/mL within 24 h. Time-kill analyses on BCG were
performed according to CLSI method M26-A.20. Experiments were
performed in triplicate [34].
3. Results
A detailed HPLC analysis of the bioconverted crude extracts from
Tan IIA by microbes and their corresponding crude extracts pro-
duced by microbes indicated that ﬁve strains, FS4-3, 3.3447, 3.246,
5e6, and 3e5 (Table S7), could produce newmetabolites compared
to the controls (Figures S1aeS1e), and the results were conﬁrmed
by ﬂask scale (50 mL). As a result, there were four new small
molecules produced by strain AS 3.3447 after incubation with the
substrate Tan IIA. The UV spectra of these new substances were
similar to those of Tan IIA, indicating that they were tanshinone
analogs.
In order to increase the reliability of the bioassay on the bio-
transformed products, we tested the antimicrobial activities of the
fractions from the crude extracts using ﬁve selected strains. This
analysis removed the inﬂuence of the activity of the substrate Tan
IIA and other natural products with antibacterial activities pro-
duced by the strain used for the biotransformation. A ﬂashchromatography column was used to generate these fractions, and
the activities were tested against four pathogens, i.e., S. aureus,
MRSA, B. subtilis, and BCG. Four fractions, frs. 3447-3, 3447-4,
3.264-6, and 3-5-1, demonstrated signiﬁcant Staphylococcus
inhibiting activities. Meanwhile, fr. 3447-3 was also found to
signiﬁcantly inhibit B. subtilis. A heat map depicted in Figure S28,
was generated and displayed different antibacterial activities
among the 27 fractions originating from crude extracts of the
highlighted strains. The shades of color represented MIC values,
with red color indicating higher activity. Fraction 3.3447e3 was
shown to be most active, followed by fr.3.3447-4.
The MS/MS networking was used to discover the molecular
environments of microbes and dereplication of natural products
[8e10]. Because structurally similar NPs share similar MS/MS
fragmentation patterns, molecular families tend to cluster together
within a network [9,10]. Successful generation of an MS/MS mo-
lecular network of biotransformed products by microbes could
therefore be used to rapidly indicate and identify bioconverted
products from substrates. The MS/MS data of the substrate, Tan IIA,
acted as “seed” spectra, which provided the initial focal point in the
network when processed with the MS/MS spectra from the bio-
transformed mixtures. Any nodes/clusters connected to that of Tan
IIA on a generated molecular network can be considered as bio-
converted products after careful conﬁrmation by their MS2
patterns.
The MS/MS data of a crude extract of the fungus M. rouxianus
3.3447 treated with Tan IIA was obtained. An MS/MS molecular
network was generated (Fig. 3a) and an FM3 layout was performed
on Cytoscape. The tanshinones molecular family (boxed and
enlarged) could be obviously mapped on the network and the ion
signal at m/z 295.13 was determined to be a molecular ion of Tan
IIA. The signals atm/z 441.15 and 459.20 were structurally similar to
Tan IIA and can thus be considered as the potential biotransformed
products. Analyzing the MS2 spectra of m/z 441 and 459 revealed
that they both contained 162 Da shift peaks (Fig. 3b). These results
indicated that glycosylation of Tan IIA occurred after treatment
with the fungus M. rouxianus 3.3447.
Bioassay-directed fractionation and puriﬁcation of a large-scale
culture of M. rouxianus 3.3447 yielded four new glycosides of tan-
shinones, tanshinosides A (1), B (2), C (3), and D (4). All structures
were assigned by detailed spectroscopic analysis as discussed
below.
The molecular formula of tanshinoside A (1) was determined as
C24H24O8 from its HREIMS ([MþH]þ, m/z 441.1540, calcd. for
C24H24O8H, 441.1549). The 13C NMR signals of the pyranose moiety
at dC 106.6, 77.5, 76.1, 74.1, 69.8, and 61.0 together with the
anomeric proton signal at dH 4.72 (d, J ¼ 8.0 Hz) suggested the
presence of a glucosyl group in the b-form [35]. Detailed analysis of
the 1H and 13C NMR spectra of 1 revealed that the structure of the
aglycone was very similar to that of tanshinone I (Tan I, 6)
(Figures S2eS3, Table 1), except that two carbonyl carbons on Tan I
were replaced by two oxygen-bearing aromatic carbons (dC 144.0
and 136.0) on 1. Tan I is a natural product previously reported from
the TCM Salvia miltiorrhiza [36]. A careful comparison of the NMR
data of 1 and Tan I revealed that 1 was a glycoside of the hydro-
quinone of Tan I. Substitution at C-12 of the glucosyl moiety of 1
could be determined by the HMBC correlations between the
anomeric proton of glucose at dH 4.72 and dC 136.0 (C-12), and was
further supported by the ROESY correlations between dH 9.75 (H-1)
and the exchangeable hydrogen at dH 10.03 (brs) (11-OH) (Fig. 4,
Figures S4eS8 and Table S1). Thus, the structure of 1 (Fig. 1) was
established and all of the signals in the 2D NMR spectra were
assigned unambiguously.
Tanshinoside B (2) was assigned the same molecular formula
C24H24O8 as 1 by HRESIMS ([MþH]þ, m/z 441.1540). The 1H and 13C
Fig. 3. Molecular network of tanshinone IIA biotransformation products of strain M. rouxianus AS 3.3447. (a) Tanshinones molecular family (boxed and enlarged) from the tan-
shinone IIA and fungus AS 3.3447 biotransformed products MS/MS clusters. (b) MS2 spectra of biotransformed products on tanshinone IIA (m/z 441.15 and 459.20) revealed
glycosylation via biotransformation.
Fig. 4. Observed 1He1H COSY, key HMBC, and ROESY correlations of 1e4.
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shift of two oxygen-bearing aromatic carbons at dC 148.9 and 137.1
(Figures S9eS10, Table 1). The above evidences revealed that 2
might possess a different glycosylation position from 1. The ROESY
correlations of H-1 at dH 9.75 (m) and the anomeric proton at dH
4.73 (d, J ¼ 8.2 Hz) (Fig. 4, Figures S11eS15 and Table S2) indicated
that the glucosyl moiety was substituted at C-11 on 2. The structure
of tanshinoside B (2) was determined as shown in Fig. 1.
HRESIMS measurements of tanshinoside C (3) revealed an
adduct ion ([MþH]þ m/z 473.1919) consistent with the molecular
formula of C26H32O8. The 13C spectrum displayed a set of NMR
signals of the hexosemoiety at dC 94.7, 77.7, 76.5, 72.1, 69.7, and 61.0.
According to 1H and 13C NMR data of 3, the structure of its aglycone
was very similar to that of tanshinone IIA (Tan IIA, 5)
(Figures S16eS17, Table 1) [36], except that two carbonyl carbons
on Tan IIA were replaced by two oxygen-bearing aromatic carbons
(dC 167.2 and 163.7) on 3 and a carbon signal at dC 51.2 of eOCH3.
The HMBC correlations of an aromatic proton at dH 7.41 (d,
J ¼ 8.2 Hz) with C-11 at dC 167.2 and an anomeric proton at dH 5.41
(d, J ¼ 7.6 Hz) and C-11 at dC 167.2 indicated that a glucosyl residue
was linked to C-11 (Fig. 4, Figures S18eS21 and Table S3). The
structure of 3 was identiﬁed (Fig. 1), and all the 2D NMR spectra
signals were assigned unambiguously.
The molecular formula of tanshinoside D (4) was determined to
be C25H30O8 based on its HREIMS ([MþH]þ,m/z 459.2066,calcd. for
459.2019). Comparing the 1H NMR data of 4 with that of 3 showed
that the proton signal of the methoxyl group disappeared
(Figures S22eS23, Table 1). It could be speculated that 4 was aglycosylation hydroquinone form of tanshinone IIA. The glycosyl-
ation position was determined by HMBC spectrum. The HMBC
correlations of an aromatic proton at dH 7.83 (d, J ¼ 8.0 Hz) with C-
11 at dC 136.2 and an anomeric proton at dH 4.41 (d, J ¼ 8.0 Hz) and
C-11 at dC 136.2 indicated that a glucosyl residue was linked to C-11
(Fig. 4, Figures S24eS27 and Table S4). The structure of 4 was
identiﬁed (Fig. 1), and all 2D NMR spectra signals were assigned
unambiguously.
All of the isolated compounds were tested for their activities
against S. aureus, MRSA, B. subtilis, BCG, and P. aeruginosa (Table 2).
Tanshinosides A (1) and B (2) showed potent activities against both
S. aureus and MRSA with MIC values ranging between 0.78 and
3.125 mg/mL. Tanshinoside C (3) was inactive with MIC
values > 100 mg/mL, while tanshinoside D (4) showed weak activ-
ities against both S. aureus and MRSAwith MIC values of 25 mg/mL.
In order to further evaluate the pharmaceutical potential of 1 and 2,
their activities were measured against two clinical isolates of
oxacillin-resistant S. aureus and 2 showed potent activity against
oxacillin-resistant S. aureus (8e24) and (6281) with MIC values of
0.78 mg/mL. Comparison of the activities of 1 and 2 against the
clinical isolates revealed that the glycosylation position of tan-
shinosides might be responsible for a different activity. However,
Tan IIA did not show any activities against these resistant isolates.
In order to determine the bactericidal property of tanshinosides
A (1) and B (2), dose-dependent experiments were carried out
using S. aureus (ATCC 6538) and MRSA (clinical strain obtained
from Chaoyang hospital) as model organisms (Fig. 5) [37]. The re-
sults indicated that 1 and 2 have similar potentials against killing
Table 2
Antimicrobial activities of tanshinosides AeD (1e4), Tan IIA and Tan I.
Organism (strain) Minimum inhibitory concentration (mg/mL)
1 2 3 4 Tan IIAa Tan Ib Control
Staphylococcus aureus (ATCC 6538) 0.78 1.56 >100 25 3.125 12.5 1c
Methicillin-resistant S. aureus (MW2) 1.56 3.125 >100 25 >100 50 1c
Oxacillin-resistant S. aureus (8e24) 3.125 0.78 >100 25 >100 50 1c
Oxacillin-resistant S. aureus (6281) 3.125 0.78 >100 25 >100 50 1c
Bacillus subtilis (ATCC 6633) 1.56 6.25 100 50 >100 >100 0.5c
Bacillus Calmette-Guerin (Pasteur 1173P2, BCG) 50 50 >100 50 3.125 25 0.05d
Pseudomonas aeruginosa (PAO1) >100 >100 >100 >100 >100 >100 1e
a Tanshinone IIA.
b Tanshinone I.
c Vancomycin.
d Isoniazid.
e Ciproﬂoxacin.
Fig. 5. The bactericidal activities of tanshinosides A (1) and B (2) against MRSA and S. aureus (SA). Compounds were added to cultures at time zero, and samples were processed as
described in the Materials and Methods. A: in vitro time-kill curve of tanshinoside A (1) against MRSA; B: in vitro time-kill curve of tanshinoside B (2) against MRSA; C: in vitro time-
kill curve of vancomycin against MRSA; D: in vitro time-kill curve of tanshinoside A (1) against SA; E: in vitro time-kill curve of tanshinoside B (2) against SA; F: in vitro time-kill
curve of vancomycin against SA.
W. He et al. / Synthetic and Systems Biotechnology 1 (2016) 187e194 193Staphylococcus bacteria as vancomycin in low concentrations, i.e.
2  MIC. The present ﬁndings demonstrate that 1 and 2 possess a
dose-dependent activity against MRSA and S. aureus on in vitro
time-kill experiments. In addition, 1 showed a better activity
against both MRSA and S. aureus than 2.4. Discussion and conclusion
The biotransformation of TCM-derived antibiotic Tan IIA by afungus AS 3.3447 provided four new compounds, the glycosides of
tanshinones, via a combination of dehydrogenation, demethyla-
tion, reduction, glycosylation, and methylation. Tanshinosides are
serial structurally unique compounds that are not discovered from
the secondary metabolites pathway of the tanshinone producing
plant. This is the ﬁrst report that describes tanshinone derivatives
could be glycosylated by incubation with microbes. Compared to
parent substrate, the activities of 1 and 2 against drug-resistant S.
aureus clinical isolates were signiﬁcant improved. This might
W. He et al. / Synthetic and Systems Biotechnology 1 (2016) 187e194194attribute to the glycosylation of the structure of Tan IIA. The
glycosylation of natural products provided a wide range of unique
substances and inﬂuence the pharmacological and pharmacoki-
netic properties of metabolites. Hence, glycosylation of natural
products is used as a viable strategy to produce bioactive com-
pounds with improved activity [38e40]. In addition, glycosides of
Tan I (1 and 2) present more potent activities against most of the
tested pathogens, compared to those of Tan IIA (3 and 4). This in-
dicates that ring A might be the necessary functional group.
Meanwhile, 1 and 2 showed different selectivity against these
pathogens, which revealed that the substituted position of glucose
moiety might correlate with their biological properties. As
concluded, tanshinosides A (1) and B (2) might act as promising
candidates for development as novel anti-MRSA therapeutic
agents. The present approach provides a new cost-effective, sus-
tainable and rapid strategy for drug discovery.
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